RyboDyn, a San Diego, CA-based biotechnology firm growing immunotherapies focusing on the darkish genome, raised $4M in Pre-Seed funding.
The spherical was led by Genedant Capital and SeaX Ventures, with participation from SOSV and Swell VC.
The corporate intends to make use of the funds to broaden goal discovery and speed up drug improvement.
Led by CEO Dr. Imad Ajjawi, RyboDyn is a biotechnology firm pioneering the event of immunotherapies focusing on the darkish genome. By leveraging RyboCypher™, a proprietary sequencing methodology and superior bioinformatics platform, it’s uncovering and validating beforehand unknown proteins and disease-specific targets. With its scalable, in-house platform for lead discovery and optimization and proprietary IP licensed from Oregon Well being and Science College, it’s driving a “targets-to-assets” strategy to therapeutic improvement.
The corporate collaborates with medical and tutorial establishments in addition to biopharma companions to validate and advance its drug pipeline, specializing in transformative options for most cancers and different illnesses with unmet medical wants.
FinSMEs
09/01/2025
